3M Drug Delivery Systems - Blog Article

3M Drug Delivery Systems Blog

  • Methodology for Uniformity of Delivered Dose

    webLoaded = "false"
    • October 28, 2016 By Andy Cooper

      Andy Cooper 3M Technical Specialist

    webLoaded = "false" Loadclientside=No
    Photo: Andy Cooper 3M Technical Specialist

    webLoaded = "false"
    • A year ago, 3M’s Drug Delivery Systems, in partnership with Mylan, launched SirduplaTM in the UK as the first therapeutic equivalent to combination asthma therapy Seretide® Evohaler®. With that launch, 3M took an important step forward in the generics space. The partnership combined 3M’s expertise in inhalation drug development and manufacturing with Mylan’s leadership position in the global generics market.

      Sirdupla on the manufacturing line in Loughborough

    webLoaded = "false" Loadclientside=No

    Photo: Sirdupla on the manufacturing line in Loughborough

    webLoaded = "false"
    • 3M has been filling, assembling and packaging Sirdupla at the Loughborough, UK manufacturing facility. By partnering with Mylan, 3M has once again proven that it is a worldwide leader in the inhalation space by putting its expertise of more than 60 years of inhalation drug development and manufacturing to work on another successful product launch.

      3M Celebrating 60 years of Inhalation Firsts

    webLoaded = "false" Loadclientside=No

    Photo: 3M Celebrating 60 years of Inhalation Firsts

    webLoaded = "false"

    webLoaded = "false" Loadclientside=No

    Seretide and Evohaler are registered trademarks of GlaxoSmithKline Group.
    Sirdupla is a trademark of Mylan Inc. 3M is a trademark of the 3M Company.© 3M 2016. All rights reserved.